Pharmaceuticals is an industry undergoing redefinition and revitalization. Five technologies and a myriad of innovations are converging to enable the creation and development of new and/or improved products. Legislation is fostering innovations and is speeding industry change. Changes in one healthcare industry sector affect the other interrelated healthcare stakeholders. The 2012 to 2020 period will be typified by healthcare industry discontinuities, innovation and change. What worked in the past will not work in the future. Pharmaceutical industry norms in 2020 will be radically different than they were at the end of 2011. The "2013 U.

S. Rx Company Planning Overview" provides insights into how the transformation of the respective United States healthcare industry stakeholders will redefine how drugs are identified, developed, reimbursed, launched, marketed, prescribed, dispensed, and taken by patients. The report is designed to assist managers in the preparation of their annual long-term strategic and marketing plans. The "2013 U.S. Rx Company Planning Overview" is designed to: 1) prompt senior management to question internal assumptions and corporate strategies in order to fight "Group Think" and refine or develop strategies to better position the company to capitalize on industry change, 2) challenge the thinking of product development and marketing teams/staffs, and 3) orient individuals new to the industry. Strategically managed companies anticipate and capitalize on industry change, innovate and prosper; the majority of companies are destined to be broken up, acquired, merged or driven out of business.